Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245514 | 0.86 | PIN1 (0.58) | RHEBPIN1PKN1PKN2CSNK1A1 | |
| SCHEMBL25387660 | 0.82 | MAPK10 (0.36) | RHEBMAPK10PSMB8GABRA1GABRG2 | |
| SCHEMBL30425274 | 0.82 | MAPK10 (0.36) | RHEBMAPK10PSMB8GABRA1GABRG2 | |
| SCHEMBL4387879 | 0.80 | IMPDH2 (0.46) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL11249156 | 0.79 | MASP2 (0.48) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL27306100 | 0.79 | IMPDH2 (0.44) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL3987184 | 0.79 | IMPDH2 (0.44) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL2712161 | 0.79 | PIN1 (0.46) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL1794997 | 0.79 | CSNK1D (0.47) | RHEBMAPK10IMPDH2IMPDH1PIN1 | |
| SCHEMBL485969 | 0.78 | GRIN1 (0.43) | RHEBMAPK10IMPDH2IMPDH1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768761-B | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-115768761-A | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| EP-4129406-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2346334-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1186322-C | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2005-01-26 | — | — | CN | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| CN-1441779-A | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | RHEB 2031/4885MAPK10 1758/4885IMPDH2 3731/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | RHEB 3202/4885MAPK10 2907/4885IMPDH2 136/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | RHEB 3851/4885MAPK10 2794/4885IMPDH2 149/4885 |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | RHEB 2928/4885MAPK10 652/4885IMPDH2 2577/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | RHEB 2485/4885MAPK10 1745/4885IMPDH2 4423/4885 |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RHEB 1004/4885MAPK10 1375/4885IMPDH2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.